Bioxytran Secures a Source of GMP Quality Camel Hemoglobin

Core Insights - Bioxytran, Inc. has secured a GMP quality source of camel hemoglobin, which is essential for developing a Universal Oxygen Carrier (UOC) [1][2] - The collaboration with the Heme Foundation involves a $10 million Joint Venture aimed at addressing global blood shortages through innovative oxygen transport solutions [2][5] - Camel hemoglobin is preferred due to its stability and resilience in harsh conditions, making it a superior alternative to cow hemoglobin [3][4] Company Developments - The partnership with the Heme Foundation positions Bioxytran as the primary contractor for the UOC project, potentially increasing donations to the foundation [2][5] - Bioxytran retains full intellectual property rights for the UOC development, which could lead to significant advancements in research and applications for their leading oxygen transport molecule, BXT-25 [5][6] - The CEO of Bioxytran emphasized that having a reliable supplier of camel hemoglobin could accelerate non-dilutive funding and innovation in oxygen transport technology [6] Industry Context - The Heme Foundation aims to provide alternatives for blood transfusions, reducing the complexity of supply chains and cold storage requirements [6] - The unique properties of camel hemoglobin, such as higher concentration and stability, could enhance the scalability and impact of the UOC project [4][3] - Bioxytran is focused on addressing critical unmet medical needs through its core platform technologies, including oxygen transport, which is crucial for conditions like stroke and Alzheimer's disease [7]